Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis
← catalyst calendarNCT06865105 · readout ≤ 499 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
120estimated
Sites
37
Countries
Canada, Czechia, France +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-04-11 | actual | When the study began enrolling |
| Primary completion | Dec 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jan 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2025-03-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Psoriatic Arthritis
Interventions
- Drug: Lutikizumab
- Drug: Risankizumab
Primary outcomes
what the primary-completion date above is the date OFPercentage of Participants With an American College of Rheumatology 50% (ACR50) Response
measured At Week 16
Number of Participants With Adverse Events (AEs)
measured Up to Week 52
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed